Gallant Survey Signals Strong Veterinary Demand for Off-the-Shelf Stem Cell Therapies

New updates have been reported about Gallant.

Gallant is positioning itself at the center of a major shift in veterinary care, as new survey data with the American Animal Hospital Association (AAHA) show widespread clinician interest in regenerative medicine for pets with inflammatory diseases. In responses from more than 1,000 U.S. small animal veterinary professionals, nearly 87% said current treatments mainly manage symptoms rather than underlying causes, and 95% expect stem cell therapy to become a standard option within the next decade.

The survey underscores a clear product-direction signal for Gallant: 93% of respondents would be more likely to offer regenerative therapy if it were off-the-shelf, ready-to-use and delivered via a simple IV protocol, aligning directly with Gallant’s development of standardized stem cell products. About 79% indicated they are likely to use or recommend stem cell therapy in future, while 43% report that pet owners are already asking about regenerative options, suggesting a growing base of demand Gallant can capture as it scales.

CEO Dr. Linda Black noted that veterinarians are actively seeking tools that go beyond symptom relief to address disease at a deeper level, reinforcing Gallant’s strategy to create therapies that target root causes rather than just inflammation control. The company is also investing in market education through GallantU, its free RACE-approved continuing education platform that offers live and on-demand courses on stem cell biology, clinical application and emerging evidence in regenerative medicine.

From a regulatory and commercialization standpoint, Gallant signaled it is moving toward conditional FDA approval of what it aims to be the first off-the-shelf stem cell therapy for cats, a milestone that would validate its platform and expand its addressable market. According to Dr. Rebecca Windsor, director of Veterinary Affairs, the company’s focus is on providing clear clinical protocols, peer-reviewed data and educational resources that reduce adoption friction and support mainstream use in everyday practice.

For executives assessing Gallant’s outlook, the survey results function as market due diligence, indicating that both veterinarians and pet owners are primed for broader adoption of regenerative solutions once standardized products are available. If Gallant can convert this intent into actual utilization through regulatory approvals, scalable manufacturing and sustained clinician education, it stands to benefit from first-mover advantage in a new category of veterinary care focused on ready-to-use stem cell therapies for inflammatory diseases in pets.